<DOC>
	<DOCNO>NCT01687400</DOCNO>
	<brief_summary>This clinical trial study potential genetic marker might use predict patient acute myeloid leukemia myelodysplastic syndrome respond decitabine . This study contribute effort find effective less toxic therapy provide durable remission significant proportion elderly AML patient .</brief_summary>
	<brief_title>Genomic Predictors Decitabine Response Patients With Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>All following : Patient must nonM3 AML MDS An adverse risk karyotype define : Complex karyotype cytogenetics , Deletion part chromosome 5 , 7 , 12 , 17 define FISH cytogenetics , Somatic TP53 mutation All following : 1 . Patient must ECOG performance status ≤ 2 . 2 . Patient must &gt; 10 % disease burden measure cytomorphology , flow cytometry , cytogenetics . 3 . Patient must peripheral white blood cell count &lt; 50,000/mcl . 4 . Patient must adequate organ function , define : 1 . Total bilirubin &lt; 1.5 x ULN 2 . AST/ALT &lt; 2.5 x ULN 3 . Serum creatinine &lt; 2.0 x ULN 5 . Patient must undergo ≤ 2 cycle prior hypomethylating agent ( decitabine azacitidine ) . 6 . Patient must enrol HRPO # 201011766 ( `` Tissue Acquisition Analysis Genetic Progression Factors Hematologic Diseases '' ) . 7 . Patient must &gt; 18 year age . 8 . Patient must able understand willing sign IRBapproved write informed consent document . Patient must pregnant nursing Patient must acute promyelocytic leukemia ( 15 ; 17 ) observe FISH . Patient must know central nervous system ( CNS ) leukemia Patient must history positive human immunodeficiency virus ( HIV ) serology Patient must history positive hepatitis C serology Patient must undergo prior allogeneic stem cell transplant Patient must uncontrolled intercurrent illness include , limited , ongoing active infection , ongoing active graftversushost disease ( GVHD ) , congestive heart failure New York Heart Association ( NYHA ) class 3 4 , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patient must radiation therapy within 14 day enrollment Patient must receive chemotherapy within 21 day enrollment acute treatmentrelated toxicity must return baseline . Patients may receive hydrea time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>